

Original article

Secondary Metabolites of *Hypericum* L. Species as Xanthine Oxidase Inhibitors

Andrija Šmelcerović¹, Žaklina Šmelcerović², Katarina Tomović³,
Gordana Kocić⁴, Aleksandra Đorđević⁵

¹ University of Niš, Faculty of Medicine, Department of Chemistry, Niš, Serbia

² University of Niš, Faculty of Medicine, Center for Biomedical Science, Niš, Serbia

³ University of Niš, Faculty of Medicine, Department of Pharmacy, Niš, Serbia

⁴ University of Niš, Faculty of Medicine, Institute of Biochemistry, Niš, Serbia

⁵ University of Niš, Faculty of Science and Mathematics, Department of Chemistry, Niš, Serbia

SUMMARY

Nine *Hypericum* species (*H. barbatum*, *H. hirsutum*, *H. linarioides*, *H. olympicum*, *H. perforatum*, *H. rochelii*, *H. rumeliacum*, *H. tetrapterum* and *H. umbellatum*) collected in Serbia were assayed for inhibitory potential against xanthine oxidase *in vitro*, on the commercial enzyme, and compared with allopurinol. Seven studied *Hypericum* species (*H. barbatum*, *H. rochelii*, *H. rumeliacum*, *H. umbellatum*, *H. perforatum*, *H. tetrapterum* and *H. olympicum*) inhibit commercial xanthine oxidase with an IC_{50} below 100 $\mu\text{g/mL}$. *H. barbatum* exerted the most potent inhibitory effect ($IC_{50} = 31.84 \pm 6.64 \mu\text{g/mL}$), followed closely by *H. perforatum* ($IC_{50} = 37.12 \pm 4.06 \mu\text{g/mL}$).

Key words: xanthine oxidase inhibition, *Hypericum*, secondary metabolites

Corresponding author:

Andrija Šmelcerović

E-mail: a.smelcerovic@yahoo.com

INTRODUCTION

Xanthine oxidase (XO) is a validated target for therapeutic treatment of gout, hyperuricemia and associated conditions, with a few XO inhibitors present on the market (1). Levels of XO in plasma are enhanced also in ischemia-reperfusion injury, hemorrhagic shock, cholecystitis, hypercholesterolemia, adult respiratory distress syndrome, carcinogenesis, which provides additional indications where XO inhibitors may exert their therapeutic potential (2).

Secondary metabolites from plants have a long tradition of being used as therapeutics in medicine (3). *Hypericum* species are traditionally used as medicinal plants all over the world (4). *H. perforatum* (St. John's wort) is one of the best chemically determined species. The investigation of *Hypericum* species have increased over the years due to evidenced bioactivities of compounds found in *H. perforatum*. Chemically, naphthodianthrones, primarily hypericin and pseudo-hypericin, phloroglucinol derivatives, especially hyperforin, and flavonoids quercetin, quercitrin,

hyperoside and rutin represent the main constituents in the *Hypericum* species (5).

Continuing our research on the chemical composition (6-11) and pharmacological activities (11-14) of *Hypericum* species, in the present study extracts of nine *Hypericum* species (*H. barbatum*, *H. hirsutum*, *H. linarioides*, *H. olympicum*, *H. perforatum*, *H. rochelii*, *H. rumeliacum*, *H. tetrapterum* and *H. umbellatum*), collected in Serbia, were evaluated for inhibitory potential against XO *in vitro*, on the commercial enzyme.

MATERIALS AND METHODS

Plant material

Table 1 contains data on the identity of nine assayed *Hypericum* species, their taxonomic placement within sections of the genus *Hypericum*, voucher numbers of the deposited herbarium specimens (Herbarium Moesicum Doljevac, Serbia), collection period and locality (15). Collection was done in the blooming stage.

Table 1. Data on the assayed *Hypericum* species

Section	Plant species	Voucher number (HMD)	Collection period	Locality
<i>Drosocarpium</i> Spach	<i>H. barbatum</i>	7280	August 2010	Suva planina, East Serbia
	<i>H. rochelii</i>	6578	July 2010	Sokobanja, East Serbia
	<i>H. rumeliacum</i>	7287	July 2010	Suva planina, East Serbia
	<i>H. umbellatum</i>	6579	July 2010	Surroundings of Piroat, South East Serbia
<i>Hypericum</i>	<i>H. perforatum</i>	7291	July 2010	Surroundings of Leskovac, South Serbia
	<i>H. tetrapterum</i>	8223	July 2010	Bosilegrad, South East Serbia
<i>Olympia</i> Spach	<i>H. olympicum</i>	7288	July 2010	Rujan planina, South Serbia
<i>Taeniocarpium</i> Jaub. & Spach	<i>H. hirsutum</i>	7282	July 2010	Suva planina, East Serbia
	<i>H. linarioides</i>	8224	July 2010	Suva planina, East Serbia

Preparation of plant extracts

The extractions were performed using 3 g dry plant material and 30 mL of ethanol, using an indirect sonication method. Sonications lasted 30 min, using a Bandelin Sonorex Digital 10 P apparatus (Bandelin). At the end of extraction, filtration was done in order to separate the extracts from the residual plant material. After washing the residues with 15 mL of ethanol, the filtrates were combined and evaporated using a rotary vacuum evaporator Büchi® Rotavapor® R-210 (Büchi). Dry extracts were then dissolved in dimethyl sulfoxide (DMSO) and stored at -20 °C until measurement.

Evaluation of xanthine oxidase inhibition

Inhibition of XO was evaluated *in vitro* on the commercial bovine milk enzyme (Sigma-Aldrich), by spectrophotometric measurement of uric acid formation at 293 nm. The assay was performed in a series of test-tubes (total volume 2150 µL) prepared in the following order: i) Test samples: 0.01 units of XO, one of the studied extracts diluted in DMSO (purity ≥ 99.5%; Sigma-Aldrich) (the final concentration of DMSO in the assay was 4.65 % v/v), 232.5 µM of xanthine (purity ≥ 99.5%; Sigma-Aldrich), and 46.5 mM TRIS-HCl buffer (pH 7.8); ii) Solvent control samples: the same amount of XO, appropriate amount of DMSO, xanthine and TRIS-HCl buffer; iii) Control samples: the same amount of XO, xanthine and TRIS-HCl buffer adjusted to the same

volume. Blank samples were prepared for each group (i-iii). The tubes were incubated at 37 °C for 15 min, and after that the reaction was stopped by adding 100 µL of perchloric acid. The difference in absorbance, calculated as a percent change of the control with appropriate amount of DMSO, which correlates to uric acid formation, was used for the determination of the percentage of enzyme inhibition. DMSO, at a final concentration of 4.65 % v/v, did not affect the enzyme assay. The evaluation of XO inhibitory potential of all samples was performed at the concentrations of 100 µg/mL. Extracts exerting inhibition greater than 50 % at 100 µg/mL were tested in a broader concentration range in order to allow calculation of IC₅₀ values. Each IC₅₀ curve was generated using four concentrations of inhibitor producing an inhibition. Positive control was allopurinol and experiments were performed in triplicate.

RESULTS AND DISCUSSION

Seven of the nine studied *Hypericum* species inhibit commercial bovine milk XO with an IC₅₀ below 100 µg/mL (Table 2). *H. barbatum* showed the most potent inhibitory effect (IC₅₀ = 31.84 ± 6.64 µg/mL). Allopurinol, an approved XO inhibitor, exhibited stronger inhibitory potential (IC₅₀ = 0.20 ± 0.03 µg/mL) than studied *Hypericum* species. The extracts of *Hypericum* species belonging to the section *Taeniocarpium* did not inhibit commercial bovine milk XO with an IC₅₀ below 100 µg/mL.

Table 2. Inhibitory activities of studied *Hypericum* species against bovine milk xanthine oxidase (IC₅₀, µg/mL)

Allopurinol		0.20 ± 0.03
Section	Plant species	IC ₅₀ (µg/mL) XO
<i>Drosocarpium</i> Spach	<i>H. barbatum</i>	31.84 ± 6.64
	<i>H. rochelii</i>	42.78 ± 9.32
	<i>H. rumeliacum</i>	43.70 ± 5.85
	<i>H. umbellatum</i>	41.40 ± 7.14
<i>Hypericum</i>	<i>H. perforatum</i>	37.12 ± 4.06
	<i>H. tetrapterum</i>	48.77 ± 7.21
<i>Olympia</i> Spach	<i>H. olympicum</i>	64.76 ± 9.14
<i>Taeniocarpium</i> Jaub. & Spach	<i>H. hirsutum</i>	> 100
	<i>H. linarioides</i>	> 100

Benedí et al. (16) determined IC_{50} 68.30 $\mu\text{g/mL}$ for the hydroethanolic standardized extract of *H. perforatum* (0.3% total hypericins), while Havlik et al. (17) determined IC_{50} 46.70 $\mu\text{g/mL}$ for the 80% aqueous ethanolic extract of *H. perforatum* and IC_{50} 55.40 $\mu\text{g/mL}$ for the methylene chloride - methanolic (50/50 $\text{CH}_2\text{Cl}_2/\text{MeOH}$) extract of *H. perforatum*.

We found earlier that there is a strong correlation between secondary metabolite contents and the infrageneric classification of Robson (15) among the nine *Hypericum* species (*H. barbatum*, *H. hirsutum*, *H. linarioides*, *H. maculatum*, *H. olympicum*, *H. perforatum*, *H. richeri*, *H. rumeliacum* and *H. tetrapterum*), collected on different locations in Serbia and the F.Y.R. Macedonia (6). It was shown that *H. barbatum* possesses higher (3.9 times) content of hypericin than *H. perforatum* (6), which is in agreement with the study of Kitanov (18), who reported that the content of total hypericins in *H. barbatum* is by 2.4 times higher than in *H. perforatum*. The potent inhibitory effect of *H. barbatum* against XO activity may be related to the high level of hypericin. Also, *H. perforatum* showed a very potent inhibitory effect against XO with an IC_{50} value of 37.12 ± 4.06 $\mu\text{g/mL}$. The highest content of hyperforin was found in *H. perforatum* (6).

CONCLUSION

Ethanolic extracts of *H. barbatum*, *H. rochelii*, *H. rumeliacum*, *H. umbellatum*, *H. perforatum*, *H. tetrapterum* and *H. olympicum* inhibit commercial bovine milk XO with an IC_{50} below 100 $\mu\text{g/mL}$. *H. barbatum* showed the highest inhibitory activity and may be potentially used in the treatment of hyperuricemia and gout.

Acknowledgements

The financial support of this work by Ministry of Education, Science and Technological Development of the Republic of Serbia (Grants No. OI 172044 and TR 31060) and internal project of Faculty of Medicine, University of Niš no. 4 is gratefully acknowledged.

References

1. Lü JM, Yao Q, Chen C. 3,4-Dihydroxy-5-nitrobenzaldehyde (DHNB) is a potent inhibitor of xanthine oxidase: a potential therapeutic agent for treatment of hyperuricemia and gout. *Biochem Pharmacol* 2013; 86(9): 1328-37.
<https://doi.org/10.1016/j.bcp.2013.08.011>
2. Radi R, Rubbo H, Bush K, Freeman B. Xanthine oxidase binding to glycosaminoglycans: kinetics and superoxide dismutase interactions of immobilized xanthine oxidase-heparin complexes. *Arch Biochem Biophys* 1997; 339: 125-35.
<https://doi.org/10.1006/abbi.1996.9844>
3. Hufsky F, Scheubert K, Böcker S. New kids on the block: novel informatics methods for natural product discovery. *Nat Prod Rep* 2014; 31: 807-17.
<https://doi.org/10.1039/c3np70101h>
4. Yazaki K, Okuda T. Medicinal and aromatic plants VI. In: Bajaj, Y.P.S. (ed), *Biotechnology in agriculture and forestry*. Springer-Verlag, Berlin, 1994: 167-78.
5. Stojanović G, Đorđević A, Šmelcerović A. Do other *Hypericum* species have medical potential as St. John's Wort (*Hypericum perforatum*)? *Curr Med Chem* 2013; 20: 2273-95.
<https://doi.org/10.2174/0929867311320180001>
6. Smelcerovic A, Spiteller M. Phytochemical analysis of nine *Hypericum* L. species from Serbia and the F.Y.R. Macedonia. *Pharmazie* 2006; 61: 251-2.
7. Smelcerovic A, Verma V, Spiteller M, et al. Phytochemical analysis and genetic characterisation of six *Hypericum* species from Serbia. *Phytochemistry* 2006; 67: 171-7.
<https://doi.org/10.1016/j.phytochem.2005.10.021>
8. Smelcerovic A, Spiteller M, Ligon AP, et al. Essential oil composition of *Hypericum* L. species from Southeastern Serbia and their chemotaxonomy. *Biochem Syst Ecol* 2007; 35: 99-113.
<https://doi.org/10.1016/j.bse.2006.09.012>
9. Verma V, Smelcerovic A, Zuehlke S, et al. Phenolic constituents and genetic profile of *Hypericum perforatum* L. from India. *Biochem Syst Ecol* 2008; 36: 201-6.
<https://doi.org/10.1016/j.bse.2007.09.003>
10. Smelcerovic A, Zuehlke S, Spiteller M, et al. Phenolic constituents of 17 *Hypericum* species from Turkey. *Biochem Syst Ecol* 2008; 36: 316-9.
<https://doi.org/10.1016/j.bse.2007.09.002>
11. Đorđević A, Lazarević J, Šmelcerović A, Stojanović G. The case of *Hypericum rochelii* Griseb. & Schenk and *Hypericum umbellatum* A. Kern. essential oils: Chemical composition and antimicrobial activity. *J Pharm Biomed Anal* 2013; 77: 145-8.
<https://doi.org/10.1016/j.jpba.2013.01.024>
12. Radulović N, Stankov-Jovanović V, Stojanović G, et al. Screening of *in vitro* antimicrobial and antioxidant activity of nine *Hypericum* species from the Balkans. *Food Chem* 2007; 103: 15-21.
<https://doi.org/10.1016/j.foodchem.2006.05.062>
13. Bonkanka CX, Smelcerovic A, Zuehlke S, et al. HPLC-MS analysis and anti-oedematogenic activity of *Hypericum grandifolium* Choisy (Hypericaceae). *Planta Med* 2008; 74: 719-25.
<https://doi.org/10.1055/s-2008-1074526>
14. Spiteller M, Özen T, Smelcerovic A, et al. Phenolic constituents and the *in vitro* antioxidant activity of the flowers of *Hypericum venustum*. *Fitoterapia* 2008; 79: 191-3.
<https://doi.org/10.1016/j.fitote.2007.11.012>
15. Robson NKB. Studies in the genus *Hypericum* L. (Guttiferae) I. Infrageneric classification. *Bull Br Mus Nat Hist (Botany)* 1977; 5: 293-355.
16. Benedí J, Arroyo R, Romero C, et al. Antioxidant properties and protective effects of a standardized extract of *Hypericum perforatum* on hydrogen

peroxide-induced oxidative damage in PC12 cells. Life Sci 2004; 75: 1263-76.

<https://doi.org/10.1016/j.lfs.2004.05.001>

17. Havlik J, Gonzalez de la Huebra R, Hejtmankova K, et al. Xantine oxidase inhibitory properties of Czech

medical plants. J Ethnopharmacol 2010; 132: 461-5.

<https://doi.org/10.1016/j.jep.2010.08.044>

18. Kitanov GM Hypericin and pseudohypericin in some *Hypericum* species. Biochem Syst Ecol 2001; 29: 171-8.

[https://doi.org/10.1016/S0305-1978\(00\)00032-6](https://doi.org/10.1016/S0305-1978(00)00032-6)

Inhibicija ksantin-oksidge sekundarnim metabolitima iz biljnih vrsta roda *Hypericum* L.

Andrija Šmelcerović¹, Žaklina Šmelcerović², Katarina Tomović³,
Gordana Kocić⁴, Aleksandra Đorđević⁵

¹ Univerzitet u Nišu, Medicinski fakultet, Katedra za hemiju, Niš, Srbija

² Univerzitet u Nišu, Medicinski fakultet, Naučnoistraživački centar za biomedicinu, Niš, Srbija

³ Univerzitet u Nišu, Medicinski fakultet, Katedra za farmaciju, Niš, Srbija

⁴ Univerzitet u Nišu, Medicinski fakultet, Katedra za biohemiju, Niš, Srbija

⁵ Univerzitet u Nišu, Prirodno matematički fakultet, Departman za hemiju, Niš, Srbija

SAŽETAK

Ispitan je uticaj devet *Hypericum* vrsta (*H. barbatum*, *H. hirsutum*, *H. linarioides*, *H. olympicum*, *H. perforatum*, *H. rochelii*, *H. rumeliacum*, *H. tetrapterum* i *H. umbellatum*) prikupljenih na području Srbije na aktivnost komercijalne ksantin-oksidge *in vitro* i upoređena sa alopurinolom. Sedam ispitivanih *Hypericum* vrsta (*H. barbatum*, *H. rochelii*, *H. rumeliacum*, *H. umbellatum*, *H. perforatum*, *H. tetrapterum* i *H. olympicum*) inhibiraju komercijalnu ksantin-oksidge sa IC₅₀ vrednostima nižim od 100 µg/mL. *H. barbatum* (IC₅₀ = 31,84 ± 6,64 µg/mL) i *H. perforatum* (IC₅₀ = 37,12 ± 4,06 µg/mL) su se pokazali kao najefikasniji inhibitori ksantin-oksidge.

Ključne reči: inhibicija ksantin-oksidge, *Hypericum*, sekundarni metaboliti